Read more

March 16, 2023
2 min read
Save

FDA committee supports approval of COVID-19 treatment Paxlovid for high-risk adults

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • The FDA’s Antimicrobial Drugs Advisory Committee voted that the overall risk-benefit of Paxlovid is favorable for adults at high risk for severe disease.
  • A trial found that Paxlovid was not associated with COVID-19 rebound.
Perspective from David R. Boulware, MD, MPH

The FDA’s Antimicrobial Drugs Advisory Committee voted Thursday to support the approval of Paxlovid for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease, hospitalization or death.

The committee voted 16-1 that the benefits of Paxlovid outweigh the risks in this population. The FDA will take the vote into consideration while making its final decision on approval, which is expected in May.

IDN0323PaxlovidAMDAC_Graphic_01_WEB

Paxlovid was granted an emergency use authorization by the FDA in December 2021 for people aged 12 years or older who test positive for SARS-CoV-2 and are at risk for severe disease. In July 2022, the FDA expanded the EUA to allow pharmacists to prescribe the drug to qualifying people immediately after testing positive for the virus.

During Thursday’s meeting, the FDA said it is looking at widening the number of people eligible for a prescription, and recommending those prescriptions be made earlier after infection.

In three phase 2/3 trials presented to the committee, no major safety concerns were identified for Paxlovid, although there are risks for serious adverse reactions due to drug-drug interactions (DDIs) — some medications must be stopped, whereas others only need dose adjustments. The DDIs should be included in labeling for Paxlovid.

In addition to efficacy against the delta variant of SARS-CoV-2, data showed that Paxlovid retained antiviral activity against the omicron variant and its major subvariants. Pfizer and the FDA said that, despite limited trial data assessing clinical efficacy against omicron, evidence suggests it is reasonable to conclude that the drug will remain effective against omicron.

“This is clinically meaningful for most individuals, although clearly it’s important to weigh the DDIs and the risks that they pose,” Adaora Adimora, MD, MPH, FIDSA, the Sarah Graham Kenan Distinguished Professor of Medicine at the University of North Carolina School of Medicine and an Infectious Disease News Editorial Board Member, said during the meeting.

“It’s also clinically meaningful for the population as a whole given the high incidence of COVID-19 in the U.S. that is ongoing. And it’s especially important given the limited availability of effective oral agents,” Adimora said.

The FDA and Pfizer found no association between Paxlovid and so-called “rebound” COVID-19, with trial data showing that viral RNA rebound and symptom rebound occurred at similar frequencies in participants who received Paxlovid and placebo.

“The applicant has shown that, as the COVID-19 pandemic has evolved with new and different variants of concern, that [there is] continued benefit in terms of the most severe outcomes of hospitalization and death,” Infectious Disease News Editorial Board Member David W. Hardy, MD, said during the meeting. “So, although they definitely did not reach [the study] endpoints, it is still showing a degree of benefit I think is necessary.”

The committee did not consider the risk-benefit of Paxlovid for children aged 12 years or older on Thursday. The FDA said the EUA for this age group will remain in place, although some members of the committee expressed support for an approval for that age group as well.

References: